Medco report: Specialty pharmacy spending driven by cancer drugs
FRANKLIN LAKES, N.J. Cancer drugs will become the biggest driver of specialty pharmacy spending, with global sales of the drugs expected to reach $80 billion by 2012, according to a new report by pharmacy benefit manager Medco Health Solutions.
Spending on cancer drugs increase by 15.1% last year – behind autoimmune disorder and multiple sclerosis drugs – with an overall contribution to drug spending of 5% during the first half of this year.
“Targeted cancer therapies have dramatically reshaped oncology and greatly benefited cancer patients,” Medco chief medical officer Robert Epstein said in a statement. “The newer cancer drugs improve survival rates since they target what fuels the cancer’s growth.”
Cancer drugs also represent a robust pipeline, with more than 800 under investigation. Many of the drugs that the Food and Drug Administration has approved in the last four years – often biotech drugs – have cost $20,000 for 12-week courses of therapy, while some have cost $10,000 a month, though the report said a regulatory approval pathway for biosimilars could help reduce the costs of biotech drug treatments.